The FDA assessed the protection and effectiveness of atidarsagene autotemcel depending on facts from 37 children who obtained atidarsagene autotemcel in two solitary-arm, open-label medical trials and in an expanded entry method.[seven] Small children who received therapy with atidarsagene autotemcel have been compared to untreated kids (all-natura